GÖTEBORG, Sweden--(BUSINESS WIRE)--Regulatory News: Vitrolife (STO:VITR): VINNOVA announced in a press release yesterday that they are going to provide support of SEK 3.6 million for Vitrolife’s research project for optimized culture media to enable the clinical use of stem cells. “It is very pleasing news and will enable more intensive work in an area that we very much believe in for the future”, says Magnus Nilsson, Vitrolife’s CEO.
